Novo Nordisk A/S

NYSE:NVOUnited States

Today

Show headlines and story abstract

• DJ Novo Nordisk A/S Stock Falls Wednesday, Underperforms Market, from 40 minutes ago by Dow Jones

  40 minutes ago by Dow Jones
  Companies Mentioned: NVO
  
  This article was automatically generated using Dow Jones technology.
  
  Shares of Novo Nordisk A/S dropped 1.7% to DKK784.60 Wednesday on what proved to be an overall poor trading session for the stock market, with the OMX Nordic 40 Index falling 0.1% to 2,749.61.
  

• DJ Novo Nordisk Is Still a Buy, Analysts Say. Slowing Growth for Ozempic and Wegovy Isn't a Problem. -- Barrons.com, from 2 hours ago by Dow Jones

  2 hours ago by Dow Jones
  Companies Mentioned: LLY, NVO
  
  By Elsa Ohlen
  
  As the battle for share in the lucrative market for obesity drugs ramps up, prolonged supply issues for Novo Nordisk's Ozempic and Wegovy, plus fears that Eli Lilly may be getting ahead, have weighed on Novo's shares. But the Danish pharma company has a card up its sleeve that analysts believe will support its story well into the 2030s.
  

• DJ Novo Nordisk Shares Unlikely to Move Ahead of New Drug Data -- Market Talk, from 4 hours ago by Dow Jones

  4 hours ago by Dow Jones
  Companies Mentioned: NVO
  
  1228 GMT - Novo Nordisk shares are likely to remain flat until results of the company's CagriSema obesity jab trial are presented later this year, Bank of America Securities analysts Sachin Jain and Graham Parry write. The company recently announced disappointing data from an experimental obesity pill while Ozempic and Wegovy prescription trends are muted and shares have fallen around 25% from the high. "CagriSema Phase 3 data in the fourth quarter has become a 'must-have' for the investment thesis." The bank lowers 2024 EPS estimates by around 2% to reflect slower Ozempic growth, and slightly slower Wegovy supply ramp-up. Its price objective moves down to 1,075 Danish kroner from 1,150 kroner and it keeps a buy rating, noting valuation is compelling. (dominic.chopping@wsj.com)
  

• Novo Nordisk Reportedly Plans to Use Air Freight to Mitigate US Port Strike Disruptions, from 6 hours ago by MT Newswires

  6 hours ago by MT Newswires
  Companies Mentioned: NVO
  06:33 AM EDT, 10/02/2024 (MT Newswires) -- Novo Nordisk (NVO) has measures in place to avoid production disruptions caused by US port strikes, news outlets reported Tuesday. According to the reports, the company's spokesperson said it plans to trans...

• DJ Novo Nordisk's New Weight-Loss Jab Could Support Co Into 2030s -- Market Talk, from 7 hours ago by Dow Jones

  7 hours ago by Dow Jones
  Companies Mentioned: NVO
  
  0900 GMT - Novo Nordisk is expected to present critical results from a trial of its CagriSema weight-loss jab trial in the fourth quarter and Deutsche Bank expects the data to re-establish Novo as the "best-in-disease offering in the injectable obesity space," supporting the Novo story well into the 2030s. The bank continues to see a positive risk-reward into the results presentation, despite concerns over near-term prescription trends and consequent hesitation into the third quarter weighing on shares recently. "We think the present weakness represents a good entry opportunity," Deutsche Bank analyst Emmanuel Papadakis writes. Deutsche bank reiterates it buy rating and 1,100 Danish kroner target price. Shares trade 0.5% lower at 794 kroner. (dominic.chopping@wsj.com)